PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS
    2.
    发明公开
    PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS 审中-公开
    VERFAHREN ZUR HERSTELLUNG VON SITAGLIPTIN SOWIE ZWISCHENPRODUKTEN DAVON

    公开(公告)号:EP2882752A1

    公开(公告)日:2015-06-17

    申请号:EP13750356.1

    申请日:2013-08-08

    申请人: Cipla Limited

    IPC分类号: C07D487/04

    CPC分类号: C07D487/04

    摘要: There is provided a process for the preparation of sitagliptin or a pharmaceutically acceptable salt thereof, and a process for the preparation of intermediate compounds useful in the preparation of sitagliptin. In particular, there is provided a process comprising condensing 3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl) butyric acid of formula (II) with 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3-a] pyrazine of formula (III) or a salt thereof in presence of a catalyst to obtain (R)-tert-butyl-4-oxo-4-(3- (trifluoromethyl)-5,6-dihydro-[ 1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)- 1 -(2,4,5- trifluorophenyl)butan-2-yl-carbamate of formula (IV) or a pharmaceutically acceptable salt thereof. The catalyst is represented by the compound of formula (V). Compound of formula (IV) or its pharmaceutically acceptable salt obtained may be deprotected to obtain a compound of formula (I).

    摘要翻译: 提供了西他列汀或其药学上可接受的盐的制备方法,以及制备可用于制备西格列汀的中间体化合物的方法。 特别地,提供了一种方法,其包括将式(II)的3-叔丁氧基羰基氨基-4-(2,4,5-三氟苯基)丁酸与3-(三氟甲基)-5,6,7,8-四氢 - [1,2,4]三唑并[4,3-a]吡嗪或其盐在催化剂存在下反应,得到(R) - 叔丁基-4-氧代-4-(3- (三氟甲基)-5,6-二氢 - [1,2,4] - 三唑并[4,3-a]吡嗪-7(8H) - 基)-1-(2,4,5-三氟苯基)丁-2- (Ⅳ)的 - - - - 氨基甲酸酯或其药用盐。 催化剂由式(V)化合物表示。 可以将得到的式(IV)化合物或其药学上可接受的盐脱保护,得到式(I)化合物。

    A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN
    7.
    发明公开
    A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN 有权
    用于生产曲坦

    公开(公告)号:EP2467373A2

    公开(公告)日:2012-06-27

    申请号:EP10747476.9

    申请日:2010-08-18

    申请人: Cipla Limited

    CPC分类号: C07D401/04 Y02P20/55

    摘要: The present invention relates to a process for preparing naratriptan or a salt thereof, the process comprising: (a) reacting a compound of formula (3) with a compound of the formula HCCR wherein Z is a protecting group, Y is a leaving group and R is a trialkyl silyl group, a trialkylstannyl group or a zinc (II) halide, to obtain the compound of formula (4); (b) converting the compound of formula (4) to a compound of formula (5) wherein Z' is hydrogen or a benzyl group; (c) converting the compound of formula (5) to naratriptan; and (d) optionally converting naratriptan to a salt thereof. The present invention also provides novel compounds (3) and (4) and processes for their preparation.